A Review of the Adverse Effects of Peripheral Alpha-1 Antagonists in Hypertension Therapy (Q24794338)

Current controlled trials in cardiovascular medicine

Europe PubMed Central

title

A Review of the Adverse Effects of Peripheral Alpha-1 Antagonists in Hypertension Therapy (English)

0 references

main subject

arterial hypertension

1 reference

Chris L Bryson CL

1

0 references

Bruce M Psaty BM MD PhD

series ordinal

2

0 references

publication date

12 April 2002

0 references

published in

1 reference

Treatment of congestive heart failure: guidelines for the primary care physician and the heart failure specialist.

volume

3

0 references

issue

1

0 references

page(s)

7

0 references

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=134479

Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=134479

alpha- and beta-adrenergic pathways differentially regulate cell type-specific apoptosis in rat cardiac myocytes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=134479

Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=134479

Catecholamine cardiotoxicity

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=134479

Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=134479

Acute and chronic haemodynamic effects of doxazosin in hypertension at rest and during exercise

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=134479

Overall safety of terazosin as an antihypertensive agent

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=134479

Effectiveness of doxazosin in systemic hypertension

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=134479

Epidemiology and natural history of benign prostatic hyperplasia.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=134479

Changes in blood viscosity accompanying the response to prazosin in patients with essential hypertension

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=134479

Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=134479

Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=134479

Increased plasma norepinephrine levels during prazosin therapy for severe congestive heart failure

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=134479

Multicenter, double-blind comparison of doxazosin and atenolol in patients with mild to moderate hypertension

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=134479

Long-term experience with terazosin for treatment of mild to moderate hypertension.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=134479

Effect of withdrawal of terazosin therapy in patients with hypertension

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=134479

Chronic effects of direct vasodilation (pinacidil), alpha-adrenergic blockade (prazosin) and angiotensin-converting enzyme inhibition (captopril) in systemic hypertension.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=134479

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

30 May 2018

1 reference

https://api.crossref.org/works/10.1186%2F1468-6708-3-7

Effects of doxazosin and atenolol on circulating endothelin-1 and von Willebrand factor in hypertensive middle-aged men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1468-6708-3-7

Reduced heat shock proteins: a mechanism to explain higher cardiovascular events associated with doxazosin

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1468-6708-3-7

Diuretic therapy for hypertension and the risk of primary cardiac arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1468-6708-3-7

Long-term effects on plasma lipids of diet and drugs to treat hypertension. Treatment of Mild Hypertension Study (TOMHS) Research Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1468-6708-3-7

The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1468-6708-3-7

Trends in antihypertensive drug therapy of ambulatory patients by US office-based physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1468-6708-3-7

Effects of prazosin therapy on BP, renal function, and body fluid composition

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1468-6708-3-7

Comparison of the safety and efficacy of once-daily terazosin versus twice-daily prazosin for the treatment of mild to moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1468-6708-3-7

Comparison of myocardial catecholamine balance in chronic congestive heart failure and in angina pectoris without failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1468-6708-3-7

Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1468-6708-3-7

Terazosin, a new selective alpha 1-adrenergic blocking agent. Results of long-term treatment in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1468-6708-3-7

Comparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemic hypertension. The Alpha Beta Canada Trial Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1468-6708-3-7

Doxazosin withdrawal and ambulatory blood pressure monitoring in normotensive subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1468-6708-3-7

Increase in plasma norepinephrine during prazosin therapy for chronic congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1468-6708-3-7

Efficacy of prazosin in the management of chronic congestive heart failure: A 6-month randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1468-6708-3-7

Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group

21 January 2018

1 reference

12 December 2020

Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group

1 reference

12 December 2020

Treatment of hypertension in patients with comorbidities: results from the study of hypertensive prescribing practices (SHyPP)

1 reference

12 December 2020

Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group

1 reference

12 December 2020